Triple negative breast cancer+1
Not recruitingStudy on Niraparib for Patients with HER2-Negative BRCA-Mutated or Triple-Negative Breast Cancer with Molecular Disease Detected by ctDNA
Study on Niraparib for Patients with HER2-Negative BRCA-Mutated or Triple-Negative Breast Cancer with Molecular Disease Detected by ctDNA
- Disease:Triple negative breast cancerHormone receptor positive HER2 negative breast cancer
- Substances:–
The Netherlands- Participants:18–64 years · 65+ years
- Sponsor:Glaxosmithkline Research & Development Limited














